[THE INVESTOR] Korea’s GC Pharma said on Nov. 5 that its US subsidiary Curevo has received approval from the US Food and Drug Administration to begin phase 1 clinical trials of CRV-101, its vaccine candidate for the prevention of herpes zoster.
Seattle-based Curevo, along with its collaborator Infectious Disease Research Institute, is on track to initiate the early-stage clinical program in the fourth quarter of 2018 in the US.
“While there have been significant recent advances in the development of new shingles vaccines, there remains a need to continue innovating novel strategies for this important health priority” Corey Casper, CRV-101 project leader at Curevo and IDRI’s chief scientific officer, said in a statement.
Shingles typically presents as a painful blistering rash that develops on one side of the body, as a result of reactivation of the virus that causes chicken pox.
The risk of shingles increases after 50 years of age. There are currently two immunization options for the prevention of shingles available in the US.
“This vaccine has been engineered with the latest advancements in protein science and immune stimulating molecules that we think should make it highly effective while minimizing the side effects that often accompany shingles vaccination,” Casper said.
CRV-101 is the first drug candidate to enter a clinical program since Curevo was set up by GC Pharma in May with a goal to give an impetus to its vaccine business.
By Park Han-na (firstname.lastname@example.org)